Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
In this study, we demonstrated that IL-33/ST2 was involved in the immunosuppression mechanism of PD-L1 antibody therapy, and blockade by sST2-Fc or anti-PD-L1-sST2 could remodel the inflammatory TME and induce potent antitumor effect, highlighting the potential therapeutic strategies for the tumor treatment by simultaneously targeting IL-33 and PD-L1.
Authors
- Kaicheng Zhou (ORCID: https://orcid.org/0009-0008-4731-1005)
- Xumeng Zhang (ORCID: https://orcid.org/0000-0002-5861-2355)
- Dianwen Ju (ORCID: https://orcid.org/0000-0002-4305-9622)
- An Zhu (ORCID: https://orcid.org/0000-0002-9821-2946)
- Xian Zeng (ORCID: https://orcid.org/0000-0002-1397-554X)
- Yanyang Nan
- Shuwen Xu (ORCID: https://orcid.org/0000-0002-3557-5897)
- Xiaozhi Hu
- Jiajun Fan (ORCID: https://orcid.org/0000-0003-3721-5745)
- Mengyang Li (ORCID: https://orcid.org/0000-0003-1491-4105)
- Jun Lin (ORCID: https://orcid.org/0000-0001-9572-2134)
- Xuebin Wang (ORCID: https://orcid.org/0000-0003-4270-7330)
- Zhonglian Cao
- Yu Bai (ORCID: https://orcid.org/0000-0002-3318-3240)
- Xuyao Zhang (ORCID: https://orcid.org/0000-0003-1654-5550)
- Yuanzhen Zhang
- Zihan Dou
- Tao Wu (ORCID: https://orcid.org/0009-0007-7864-6695)
Institutions
- Fudan University (CN)
- University of Michigan (US)
- Shanghai Children's Hospital (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1136/jitc-2024-009236
- Citations
- 15
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 3.61
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China